SEC Form 4 · accession 0001179110-15-012865
AMAG PHARMACEUTICALS INC. · AMAG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Geoffrey Crouse
Officer — EVP
Period of report
Aug 31, 2015
Accepted (ET)
Sep 2, 2015 · 4:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000792977
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Aug 31, 2015 | A | 18,750 | — | A | 18,750 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F3 | $62.54 | Aug 31, 2015 | A | 37,500 | A | — | Aug 31, 2025 | Common Stock | 37,500 | 37,500 | D |
Explanation of responses
- F1These shares of common stock are issuable pursuant to a grant of restricted stock units that vests in three equal annual installments commencing on August 31, 2016. Each restricted stock unit represents a contingent right to receive one share of AMAG Pharmaceuticals, Inc. common stock.
- F2Not applicable.
- F3This option vests and becomes exercisable in four equal annual installments commencing August 31, 2016.